Drugs List

Therapeutic Indications

Uses

Hyperkeratosis
Ichthyosis
Skin disorder - dry or scaly

Contraindications

None known

Precautions and Warnings

Breastfeeding
Severe renal impairment

Avoid broken or inflamed skin
Avoid contact with eyes
Avoid contact with mucous membranes
Breastfeeding: Wash product off breasts prior to breastfeeding infant
May enhance efficacy of other topical products
Stinging or burning may occur if applied to broken/abraded skin
Advise patient residue on clothing/bedding may cause fire hazard

Urea increases penetration of other drugs into the skin. This has been demonstrated for corticosteroids, dithranol and 5 fluorouracil.

Pregnancy and Lactation

Pregnancy

At the time of writing there is limited published information regarding the use of urea with lactic acid cream 10% + 5% during pregnancy.

The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).

Lactation

At the time of writing there is limited published information regarding the use of urea with lactic acid cream 10% + 5% during lactation.

The cream should be removed from the breast area before breastfeeding.

Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
Specialist advice is available from the UK Drugs in Lactation Advisory Service at https://www.midlandsmedicines.nhs.uk/content.asp?section=6&subsection=17&pageIdx=1

Side Effects

Smarting

Presentation

Topical formulations of urea with lactic acid.

Drugs List

Therapeutic Indications

Uses

Hyperkeratosis
Ichthyosis
Skin disorder - dry or scaly

Dosage

Adults

Children

Contraindications

None known

Precautions and Warnings

Breastfeeding
Severe renal impairment

Avoid broken or inflamed skin
Avoid contact with eyes
Avoid contact with mucous membranes
Breastfeeding: Wash product off breasts prior to breastfeeding infant
May enhance efficacy of other topical products
Stinging or burning may occur if applied to broken/abraded skin
Advise patient residue on clothing/bedding may cause fire hazard

Urea increases penetration of other drugs into the skin. This has been demonstrated for corticosteroids, dithranol and 5 fluorouracil.

Pregnancy and Lactation

Pregnancy

At the time of writing there is limited published information regarding the use of urea with lactic acid cream 10% + 5% during pregnancy.

The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).

Lactation

At the time of writing there is limited published information regarding the use of urea with lactic acid cream 10% + 5% during lactation.

The cream should be removed from the breast area before breastfeeding.

Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
Specialist advice is available from the UK Drugs in Lactation Advisory Service at https://www.midlandsmedicines.nhs.uk/content.asp?section=6&subsection=17&pageIdx=1

Side Effects

Smarting

Overdosage

It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

The following number will direct the caller to the relevant local centre (0844) 892 0111

Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).

Further Information

Last Full Review Date: March 2018

Reference Sources

Summary of Product Characteristics: Calmurid cream. Galderma (U.K) Ltd. Revised October 2017.